Table 1 Clinical characteristics of study subjects.

From: Prolonged bedrest reduces plasma high-density lipoprotein levels linked to markedly suppressed cholesterol efflux capacity

  Pre-bedrest baseline Day 21 of bedrest p-value
Bedrest group
N 11 11  
Total cholesterol (mg/dL) 143.5 ± 20.0 122.0 ± 21.2 0.001
HDL-cholesterol (mg/dL) 36.8 ± 6.7 30.0 ± 6.8 0.001
LDL-cholesterol (mg/dL) 90.2 ± 15.9 79.6 ± 16.1 0.040
Total triglyceride (mg/dL) 82.6 ± 19.8 62.2 ± 13.3 0.014
Plasma apoA-I (mg/dL) 120.4 ± 13.7 97.8 ± 14.9 0.001
Plasma apoA-II (mg/dL) 36.0 ± 4.2 30.4 ± 2.8 0.002
Plasma SAA (mg/dL) 0.5 (0.2–0.6) 0.3 (0.2–0.9) 0.624
Bedrest plus RVE group
N 11 11  
Total cholesterol (mg/dL) 161.1 ± 28.1 130.2 ± 24.4 0.002
HDL-cholesterol (mg/dL) 38.3 ± 6.7 29.8 ± 5.0 0.001
LDL-cholesterol (mg/dL) 102.9 ± 22.2 87.4 ± 20.0 0.029
Total triglyceride (mg/dL) 99.8 ± 34.7 65.1 ± 16.8 0.002
Plasma apoA-I (mg/dL) 127.3 ± 16.6 97.3 ± 9.5 0.001
Plasma apoA-II (mg/dL) 39.1 ± 3.2 30.6 ± 3.1 0.001
Plasma SAA (mg/dL) 0.8 (0.5–1.0) 0.8 (0.5–1.0) 0.966
  1. HDL-cholesterol, low-density lipoprotein cholesterol, total cholesterol, triglycerides, apoA-I, apoA-II and SAA were evaluated in plasma for the bedrest (n = 11) and the bedrest plus resistive vibration exersise (n = 11) groups. Data are presented as mean ± SD (normally distributed data), or as median with interquartile range (not normally distributed data). Differences between pre-bedrest baseline and day 21 of bedrest were analyzed either with the paired t test, two-tailed (for normally distributed data), or with the Wilcoxon matched-pairs signed rank test, two-tailed (for not normally distributed data). Significance level for the analyses was set to α = 0.05 and differences are indicated with the corresponding p-value.
  2. apoA-I apolipoprotein A-I, apoA-II apolipoprotein A-II, HDL high-density lipoprotein, LDL low-density lipoprotein, N number of subjects, RVE resistive vibration exercise, SAA serum amyloid A.